Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | TGM2 | P21980 | 1/20 | 0.43 |
| ▸ | KEAP1 | Q14145 | 3/20 | 0.43 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.41 |
| ▸ | TPSAB1 | Q15661 | 3/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.40 |
| ▸ | TPSD1 | Q9BZJ3 | 2/20 | 0.40 |
| ▸ | TPSG1 | Q9NRR2 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL8101580 | 0.85 | LMNA (0.71) | SMN1; SMN2LMNAHTTTGM2KEAP1 | |
| SCHEMBL375858 | 0.83 | LMNA (0.73) | SMN1; SMN2LMNAHTTTGM2KEAP1 | |
| SCHEMBL5511344 | 0.81 | LMNA (0.61) | SMN1; SMN2LMNAHTTTGM2KEAP1 | |
| Hydrochloric Acid SCHEMBL3259897 | 0.81 | LMNA (0.71) | SMN1; SMN2LMNAHTTTGM2KEAP1 | |
| SCHEMBL12126861 | 0.80 | KEAP1 (0.59) | SMN1; SMN2LMNAHTTTGM2KEAP1 | |
| SCHEMBL20597770 | 0.80 | LMNA (0.48) | SMN1; SMN2LMNAHTTTGM2KEAP1 | |
| SCHEMBL20425048 | 0.79 | SMN1; SMN2 (0.44) | SMN1; SMN2LMNAHTTTGM2KEAP1 | |
| SCHEMBL10444759 | 0.78 | PLAU (0.60) | SMN1; SMN2LMNAHTTTGM2KEAP1 | |
| SCHEMBL11526146 | 0.78 | ALDH1A1 (0.60) | SMN1; SMN2LMNAHTTL3MBTL1MAPT | |
| SCHEMBL6615198 | 0.77 | TOP2A (0.46) | SMN1; SMN2LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1269813-C | Imidazolo-5-yl-2-anilino-pyrimidines as agents for inhibition of cell proliferation | ASTRAZENECA AB (SE) | 2006-08-16 | — | — | CN | disclosed |
| US-20060004033-A1 | Imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation | ASTRAZENECA AB | 2006-01-05 | — | — | US | disclosed |
| US-6969714-B2 | Imidazolo-5-YL-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation | ASTRAZENECA AB (SE) | 2005-11-29 | — | — | US | disclosed |
| EP-1351958-B1 | IMIDAZOLO-5-YL-2-ANILINO-PYRIMIDINES AS AGENTS FOR THE INHIBITION OF THE CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2004-06-16 | — | — | EP | disclosed |
| WO-2002020512-A9 | IMIDAZOLO-5-YL-2-ANILINO-PYRIMIDINES AS AGENTS FOR THE INHIBITION OF THE CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2004-05-06 | — | — | WO | disclosed |
| US-20040014776-A1 | Imidazolo-5-YL-2anilino-pyrimidines as agents for the inhibition of the cell proliffration | ASTRAZENECA AB (SE) | 2004-01-22 | — | — | US | disclosed |
| CN-1452620-A | Imidazolo-5-yl-2-anilino-pyrimidines as agents for inhibition of cell proliferation | ASTRAZENECA AB (CH) | 2003-10-29 | — | — | CN | disclosed |
| EP-1351958-A1 | IMIDAZOLO-5-YL-2-ANILINO-PYRIMIDINES AS AGENTS FOR THE INHIBITION OF THE CELL PROLIFERATION | AstraZeneca AB (SE) | 2003-10-15 | — | — | EP | disclosed |
| WO-2002020512-A1 | IMIDAZOLO-5-YL-2-ANILINO-PYRIMIDINES AS AGENTS FOR THE INHIBITION OF THE CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2002-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004033-A1 | Imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation | MKI67, CCNI, CCNT1 | SMN1; SMN2 2007/4885LMNA 574/4885HTT 4348/4885 |
| US-20040014776-A1 | Imidazolo-5-YL-2anilino-pyrimidines as agents for the inhibition of the cell proliffration | CCNI, TYMP, MKI67 | SMN1; SMN2 2609/4885LMNA 764/4885HTT 4573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.